Premium
Improved metabolic control decreases platelet activation markers in patients with type‐2 diabetes
Author(s) -
Eibl N.,
Krugluger W.,
Streit G.,
Schrattbauer K.,
Hopmeier P.,
Schernthaner G.
Publication year - 2004
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2004.01320.x
Subject(s) - type 2 diabetes , platelet activation , metabolic control analysis , diabetes mellitus , medicine , platelet , endocrinology , cardiology
Background Cardiovascular disease is associated with platelet dysfunction in patients with diabetes. Hyperglycaemia is known as an independent risk factor for micro‐ and macrovascular complications, and improvement of metabolic control has shown beneficial effects on diabetic late complications. Our study attempts to clarify the effect of improved metabolic control on platelet activation markers in patients with type‐2 diabetes. Materials and methods Thirty patients were studied at baseline and 3 months after improvement of metabolic control and compared with an age‐matched nondiabetic control group. Platelet activation markers (CD31, CD36, CD49b, CD62P and CD63) were assessed by flow cytometry analysis. Results Significantly more activated platelets were detected in patients with diabetes compared with controls. After 3 months’ improvement of metabolic control, a significant decline of all platelet activation markers except CD36 was noted. Furthermore a significant correlation between CD62P, CD63 and HbA 1c levels was observed. Conclusions We conclude therefore that improvement of metabolic control has a beneficial effect on platelet activation. This may have an implication in the pathogenesis of vascular disease in patients with type‐2 diabetes.